Bank of Hawaii’s Regeneron Pharmaceuticals REGN Stock Holding History

Bank of Hawaii’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$594K	Sell	952 -72	-7%	-$49K	0.03%	167
2026 Q1	$791K	Sell	1,024 -25	-2%	-$19.1K	0.04%	149
2025 Q4	$810K	Buy	1,049 +26	+3%	+$17.7K	0.04%	156
2025 Q3	$575K	Buy	1,023 +276	+37%	+$156K	0.03%	176
2025 Q2	$392K	Buy	+747	New	+$417K	0.02%	203
2020 Q4	–	Sell	-361	Closed	-$202K	–	270
2020 Q3	$202K	Sell	361 -150	-29%	-$91K	0.01%	246
2020 Q2	$319K	Sell	511 -676	-57%	-$384K	0.02%	234
2020 Q1	$580K	Buy	+1,187	New	+$490K	0.05%	185
2019 Q2	–	Sell	-1,383	Closed	-$568K	–	337
2019 Q1	$568K	Buy	1,383 +278	+25%	+$114K	0.04%	223
2018 Q4	$413K	Sell	1,105 -953	-46%	-$349K	0.04%	253
2018 Q3	$832K	Buy	2,058 +333	+19%	+$127K	0.06%	190
2018 Q2	$595K	Buy	1,725 +205	+13%	+$64.1K	0.05%	217
2018 Q1	$523K	Buy	+1,520	New	+$529K	0.04%	230

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Bank of Hawaii's REGN Position: Q2 2026 in Review

Bank of Hawaii reduced its Regeneron Pharmaceuticals (REGN) stake by 7% in Q2 2026, selling an estimated $49K and leaving 952 shares worth $594K. The position accounts for 0.03% of the portfolio, ranked #167.

Bank of Hawaii first reported a position in REGN in Q1 2018 and has held it in 13 quarters since. The position peaked at $832K in Q3 2018. 1,338 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Bank of Hawaii held 952 shares of Regeneron Pharmaceuticals worth $594K as of Q2 2026.
Bank of Hawaii sold 72 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $49K.
Regeneron Pharmaceuticals made up 0.03% of Bank of Hawaii's portfolio in Q2 2026, its #167 holding.
Bank of Hawaii first reported a position in Regeneron Pharmaceuticals in Q1 2018 and has held it in 13 quarters since.
Bank of Hawaii's Regeneron Pharmaceuticals position peaked at $832K in Q3 2018.
1,338 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Bank of Hawaii's 13F filing for Q2 2026, filed 14 Aug 2026.